Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Atrium Therapeutics, Inc.NASDAQ: RNA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin of $20.11M in Q1 FY2026
Q1 FY2026 selling, general & admin was $20.11M.
Context
- Selling, general & admin amounted to 223.8% of revenue in FY2025.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $92.66M (+122.3%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $20.11M-33.9% QoQ
- Last fiscal yearDec 2025
- $41.68M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | +122.3% | — |
| 3-year CAGR | — | -47.7% | — |
| 5-year CAGR | +0.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 41.68M USD
- Year-over-year change
- —
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.68M | — |
Selling, General & Admin vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Selling, General & Admin figures are available to compare.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 18.62M |
| Cost of Revenue | 0 |
| Gross Profit | 18.62M |
| Gross Margin | 100.0% |
| Research & Development | 53.76M |
| Selling, General & Admin | 41.68M |
| Operating Expenses | 95.43M |
| Depreciation & Amortization | 323K |
| EBITDA | (76.5M) |
| EBITDA Margin | -410.9% |
| Operating Income | (76.81M) |
| Operating Margin | -412.6% |
| Interest Income | 0 |
| Interest Expense | 0 |
| Other Income / Expenses | (12K) |
| Income Before Tax | (76.83M) |
| Pre-Tax Margin | -412.6% |
| Income Tax Expense | (142K) |
| Net Income | (76.68M) |
| Net Margin | -411.9% |
| EPS (Basic) | (4.48) |
| EPS (Diluted) | (4.48) |
| Weighted Avg Shares | 17.11M |
| Weighted Avg Shares (Diluted) | 17.11M |
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.